ARIAD Announces Full Enrollment in Phase 2 ALTA Trial of Brigatinib
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
ARIAD Pharma (ARIA) Announces Completion of Brigatinib Phase 2 ALTA Enrollment
September 15, 2015 7:36 AM EDTARIAD Pharma (NASDAQ: ARIA) announced that it has achieved full enrollment in the pivotal Phase 2 ALTA trial of its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib. This registration study enrolled approximately 220 patients at approximately 75 sites in North America, Europe and Asia.
We are proud to have completed patient enrollment in the ALTA trial in the timeframe we established at the outset, stated Timothy P. Clackson, president of research and... More
